

December 4, 2020

Cuorips Inc.

## Private Placement of New Shares

**Tokyo, Japan (December 4, 2020)** - Cuorips Inc. (HO: Chuo-ku, Tokyo; President: Takayuki Kusanagi) hereby announce that roughly 2 billion yen was raised through private placement of new shares to Taiko Pharmaceutical Co., Ltd. (HO:Osaka-shi Osaka),Kyoto University Innovation Capital Co.,Ltd. (HO : Sakyo-ku, Kyoto) , Terumo Corporation, (HO : Shibuya-ku Tokyo) , DAI-DAN Co.,Ltd. (HO : Osaka-shi, Osaka) , StemCell Institute. (HO : Minato-ku Tokyo) and ASAHI INTECC CO., LTD. (HO:Seto-shi Aichi) etc..

(For reference)

### 1: Cuorips Inc.

Cuorips Inc. is a start-up company, established in March 2017, based on technology and research results of Osaka University, for the purpose of development and commercialization of iPS cell-derived cardiomyocyte sheets.

Cuorips is developing production process technology of iPS cell-derived cardiomyocyte sheets to increase efficiency, and to obtain Japanese government approval as the world's 1st regenerative medicines for severe heart failures.

### 2: iPS cell-derived cardiomyocyte sheets

An allogeneic cell therapeutic product mainly composed of cardiomyocytes (iPS myocardium), differentiated from human iPS cells are processed into a sheet and will be transplanted onto the surface of patient's heart. Therapeutic effects such as improvement of heart function and recovery of heart failure can be expected to the patients with severe heart failure such have no treatment options.

[Inquiries regarding this matter]

Cuorips Inc. Public Relations: Kobayashi and Hirata

Website: <https://cuorips.co.jp>

Contact Info. E-mail: [info@cuorips.co.jp](mailto:info@cuorips.co.jp)